These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 15731177)

  • 1. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.
    Bennett JM; Kaminski MS; Leonard JP; Vose JM; Zelenetz AD; Knox SJ; Horning S; Press OW; Radford JA; Kroll SM; Capizzi RL
    Blood; 2005 Jun; 105(12):4576-82. PubMed ID: 15731177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma.
    Roboz GJ; Bennett JM; Coleman M; Ritchie EK; Furman RR; Rossi A; Jhaveri K; Feldman EJ; Leonard JP
    Leuk Res; 2007 Aug; 31(8):1141-4. PubMed ID: 17475326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy-related acute myeloid leukaemia and myelodysplastic syndrome in Victoria, Australia 2003-2014.
    Ong DM; Farrugia H; Wei A
    Intern Med J; 2018 Jul; 48(7):822-829. PubMed ID: 29236346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab.
    Elstrom RL; Ruan J; Christos PJ; Martin P; Lebovic D; Osborne J; Goldsmith S; Greenberg J; Furman RR; Avram A; Putman R; Chapman E; Mazumdar M; Griffith K; Coleman M; Leonard JP; Kaminski MS
    Leuk Lymphoma; 2015 Feb; 56(2):342-6. PubMed ID: 24730538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement.
    Mones JV; Coleman M; Kostakoglu L; Furman RR; Chadburn A; Shore TB; Muss D; Stewart P; Kroll S; Vallabhajosula S; Goldsmith SJ; Leonard JP
    Leuk Lymphoma; 2007 Feb; 48(2):342-8. PubMed ID: 17325895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas.
    Fisher RI; Kaminski MS; Wahl RL; Knox SJ; Zelenetz AD; Vose JM; Leonard JP; Kroll S; Goldsmith SJ; Coleman M
    J Clin Oncol; 2005 Oct; 23(30):7565-73. PubMed ID: 16186600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.
    Hosing C; Munsell M; Yazji S; Andersson B; Couriel D; de Lima M; Donato M; Gajewski J; Giralt S; Körbling M; Martin T; Ueno NT; Champlin RE; Khouri IF
    Ann Oncol; 2002 Mar; 13(3):450-9. PubMed ID: 11996478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of 131I-tositumomab.
    Lewington V
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S50-6. PubMed ID: 15786026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A clinical and scientific overview of tositumomab and iodine I 131 tositumomab.
    Zelenetz AD
    Semin Oncol; 2003 Apr; 30(2 Suppl 4):22-30. PubMed ID: 12728404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The radioisotope contributes significantly to the activity of radioimmunotherapy.
    Davis TA; Kaminski MS; Leonard JP; Hsu FJ; Wilkinson M; Zelenetz A; Wahl RL; Kroll S; Coleman M; Goris M; Levy R; Knox SJ
    Clin Cancer Res; 2004 Dec; 10(23):7792-8. PubMed ID: 15585610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study.
    Link BK; Martin P; Kaminski MS; Goldsmith SJ; Coleman M; Leonard JP
    J Clin Oncol; 2010 Jun; 28(18):3035-41. PubMed ID: 20458031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era.
    Morton LM; Dores GM; Schonfeld SJ; Linet MS; Sigel BS; Lam CJK; Tucker MA; Curtis RE
    JAMA Oncol; 2019 Mar; 5(3):318-325. PubMed ID: 30570657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab.
    Kaminski MS; Radford JA; Gregory SA; Leonard JP; Knox SJ; Kroll S; Wahl RL
    J Clin Oncol; 2005 Nov; 23(31):7985-93. PubMed ID: 16204016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.
    Kaminski MS; Zelenetz AD; Press OW; Saleh M; Leonard J; Fehrenbacher L; Lister TA; Stagg RJ; Tidmarsh GF; Kroll S; Wahl RL; Knox SJ; Vose JM
    J Clin Oncol; 2001 Oct; 19(19):3918-28. PubMed ID: 11579112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma.
    Vose JM; Bierman PJ; Enke C; Hankins J; Bociek G; Lynch JC; Armitage JO
    J Clin Oncol; 2005 Jan; 23(3):461-7. PubMed ID: 15534357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 131I-tositumomab therapy as initial treatment for follicular lymphoma.
    Kaminski MS; Tuck M; Estes J; Kolstad A; Ross CW; Zasadny K; Regan D; Kison P; Fisher S; Kroll S; Wahl RL
    N Engl J Med; 2005 Feb; 352(5):441-9. PubMed ID: 15689582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.
    Epperla N; Pham AQ; Burnette BL; Wiseman GA; Habermann TM; Macon WR; Ansell SM; Inwards DJ; Micallef IN; Johnston PB; Markovic SN; Porrata LF; Colgan JP; Ristow KM; Nowakowski GS; Witzig TE
    Br J Haematol; 2017 Aug; 178(3):427-433. PubMed ID: 28466487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma.
    Dosik AD; Coleman M; Kostakoglu L; Furman RR; Fiore JM; Muss D; Niesvizky R; Shore T; Schuster MW; Stewart P; Vallabhajosula S; Goldsmith SJ; Leonard JP
    Cancer; 2006 Feb; 106(3):616-22. PubMed ID: 16362977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of white blood cell growth factors and risk of acute myeloid leukemia or myelodysplastic syndrome among elderly patients with non-Hodgkin lymphoma.
    Gruschkus SK; Lairson D; Dunn JK; Risser J; Du XL
    Cancer; 2010 Nov; 116(22):5279-89. PubMed ID: 20665502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.